

# Eastwood Bio-Medical Canada Inc. (EBM) September 10, 2018



1130-4871 Shell Road, Richmond, BC, Canada  
V6X 3Z6



## Forward-Looking Statement

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Eastwood Bio-Medical Canada Inc. (the Company) and the Company's affiliates, including expectations and assumptions concerning TSX Venture Exchange approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

# Disclaimer

Although the data found in this Investor Deck have been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis.

Changes may be periodically made to the information herein; these changes may or may not be incorporated in any new versions of this Investor Deck. It is recommended that careful attention be paid to the contents of any information associated with a file, and that the originator of the data or information be contacted with any questions regarding appropriate use. If you find any errors or omissions, please report them to [info@eastwoodcos.com](mailto:info@eastwoodcos.com).

Notwithstanding claims or statements made by any officer, director, employee, related party, or affiliate of Eastwood Bio-medical Canada in any form including written or verbal, EBM makes no claims regarding any products it distributes or manufactures except for the sanctioned claims referred to in slide 4 of this Investor Deck. Readers should consider only these claims when evaluating this document.

# Disclaimer

Except for the claims allowed by Health Canada Product Licenses 80000196, 80000364, 80000365, 80000477, 80000481, 80000504, 80000866, the Singapore Health Science Authority CDA (HSU) 40:43/01-B(V), the National Pharmaceutical Administration NPA (CPM) 6:06 /1 Vol 19, the Food and Drug Administration Authority (Republic of China) 0900027995, the Food and Drug Administration Authority (Peoples Republic of China) Import Food Hygiene Supervision and Inspection Bureau Certificate 990067, the Food and Drug Administration Authority Approval Number J20060001, neither Eastwood Bio-Medical Canada Inc., its affiliated companies, its employees, its distributors, nor its personnel make any claims that the products distributed by Eastwood Bio-medical Canada cure, diagnose, or, prevent any diseases.

# Disclaimer

Eastwood Bio-medical Canada Inc. (EBM) is not liable for any information provided on this Investor Deck with regard to recommendations regarding the mentioned products for any health purposes. The products or claims made about specific nutrients or products have not been evaluated by the United States Food and Drug Administration. Dietary products are not intended to treat, prevent or cure disease. Consult with a healthcare professional before starting any diet, supplement or exercise program. EBM makes no guarantee or warranty with respect to any products or services sold. EBM is not responsible for any damages for information provided by the Investor Deck even if EBM has been advised of the possibility of damages. Statements regarding potential health benefits from taking EBM products that appear on this website have not been evaluated by the FDA, and may not have been evaluated by any other governmental body.



**Eastwood Bio-Medical Canada Inc. is located at Richmond, British Columbia, Canada near the Vancouver International Airport.**

# Canadian History in Diabetes Leadership

Canada has long been considered the global pioneer of the diabetes industry. In 1922, Frederick Grant Banting discovered insulin, which is considered one of the most important discoveries of the 20th century. The Nobel Foundation awarded his team the Nobel Prize in Physiology and Medicine in 1923.



# Who We Are

A company specializing in metabolic disorders such as diabetes, obesity, hypertension, and Alzheimer's disease.

We have successfully developed over 70 Eleotin® products including over 60 Health Canada (Canadian FDA) approved products.

Advertising Standards Canada (ASC) approved our flagship product, Eleotin® Bentley to be marketed as “**World's #1 Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada**”.

Please see Disclaimers on slides 3, 4, and 5.

# Advertising Standards Canada Approval Number



Electin®

World's No. 1 Doctor Recommended: over 3,000<sup>1</sup>

Newspaper & Television Acclaims: over 2500  
(Including New York Times #1 best sellers)

Researched/Clinically Tested by Universities and Governments<sup>2</sup>

Over 4 Professional Medical Associations Strongly Recommended

More than 200,000 (and rapidly growing numbers of) Users

World's #1 Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada.

ASC NCP  
 Approved / Approuvé  
 DEC 15 2014  
 ASC No./No. NCP: DP536486-E  
 Validity / Validité: \_\_\_\_\_  
 Date de péremption: \_\_\_\_\_  
 Consumer Drug Section / Division des médicaments  
 101, rue de la Loi

Bentley ELEOTIN  
 All Natural Source Capsules  
 90 Capsules

Helps Promote Healthy Blood Glucose  
 All Natural Source Ingredients

<sup>1</sup> Category: Natural Source Healthy Blood Glucose Promoting Products Available in Canada.  
<sup>2</sup> By research from University of London, University of Cambridge, Harvard Medical School, and Drug Administration of Government of Punjab, Hyderabad, India.  
 This product may not be right for you. Always read and follow the label.  
 Natural Product Number: 25779 0024094

Please see Disclaimers on slides 3, 4, and 5.

# Who We Are

**As of 2018, over 500,000 users are estimated to have used and benefited from Eleotin®. (An estimated 200,000 users as of 2014, or as of the ASC approval stamp)**

**More than four international health associations strongly recommend (endorsed) Eleotin®.**

**Eleotin® was the recipient of Best Diabetic & Hypertension Management Drug of the Year 2010\*, and**

**7th Annual International Brand Packaging Gold Award.**

\*Institute for Government Research & Leadership Technology, Nigeria  
Please see Disclaimers on slides 3, 4, and 5.

# EBM: The Recent Focus of Financial Analysts and Investors

Company production capacity 'recently' has increased to:

- Up to 3 million capsules can be produced and 10,000 bottles can be packaged per day.
- A half million dollar worth of products in retail value can be produced daily.
- Up to \$7 million in possible savings in annual manufacturing costs.



# EBM: The Recent Focus of Financial Analysts and Investors



# EBM: The Recent Focus of Financial Analysts and Investors

New Product Approvals and Licenses (Over 100 NPN Numbers).



## June 29 2018, Eastwood Bio-Medical Canada Enters Binding Terms for Asian Exports

- On June 29 2018, EBM announced entering binding terms for Asian exports. The Company is optimistic that this will result in an increase in revenues.
- New manufacturing capabilities allow the Company to finally start producing highly advanced and complex products with the best quality and process control on a meaningfully larger scale.
- The facilities and operations meet Good Manufacturing Practices standards, and retain site licenses from Health Canada and a foreign government.
- EBM is no longer being bound by production limitations.

# Stock Draws International Attention



## We're Excited To See How Eastwood Bio-Medical Canada (CVE:EBM) Uses Its Cash Hoard To Grow

Simply Wall St March 2, 2020


HOME TRY OUR FREE RESEARCH TOOL AAPL GOOG FB MSFT GE JNJ TSLA ABOUT



TSXV:EBM

EBM'S INVESTMENT OVERVIEW

Eastwood Bio-Medical Canada



Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

Given this risk, we thought we'd take a look at whether **Eastwood Bio-Medical Canada** ( [CVE:EBM](#) ) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business's cash, relative to its cash burn.

# Stock Draws International Attention

## Forget Marijuana: These 2 Unknown Canadian Stocks Have Returned up to 6,570% in 2018

Brian Paradza, CFA | December 18, 2018 | More on: [EBM](#) [POG](#)

# Stock Draws International Attention

MARKETS

TSXV Biggest Percentage Gainers  
Mid-Afternoon: Eastwood Bio  
Medical, Senator Minerals, Ultra  
Lithium

CONTRIBUTOR


MT Newswires — [MTNewswires](#)

PUBLISHED

APR 18, 2016 2:37AM EDT




# Market Potential: Prevalence of Diabetes By IDF Region




# Market Potential: Prevalence of Alzheimer's and Dementia

Alzheimer's and dementia patients worldwide



# Market Potential: Prevalence of Hypertension

## Global Prevalence of Hypertension over 1.3 Billion



# Market Values of Diabetes, Hypertension and Alzheimer's

- Type 2 diabetes market to more than double, to **\$64 billion** by **2026**
- Global hypertension market will reach USD **\$32 billion** by the end of **2020**
- The global Alzheimer's market is expected to **\$10.4 billion** in **2021**

1. GlobalData's report: PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026
2. Technavio
3. GBI Research - Alzheimer's Disease Therapeutics Market to 2021

# Our Claim: The Only Option

**We believe that our products are the ‘only’ natural sourced option for those inflicted with these diseases.**

**We also believe we will remain the only option in the near future.**

**Here is why...**

Please see Disclaimers on slides 3, 4, and 5.

# Advantage #1: Modes of Action Known

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
Known - Can be used with other pharmaceutical drugs	Unknown	Unknown	Unknown	Known - Can be safely used with other pharmaceutical drugs

- The Modes of Actions for most non-pharmaceutical treatments are unproven. They can not be used with pharmaceutical drugs out of fear of unknown adverse interactions.
- Eleotin®'s modes of actions are known and proven. Eleotin® is safe when used with oral pharmaceutical drugs and insulin.
- In fact, Eleotin® reduces the side effects and resistance of oral pharmaceutical drugs and insulin. When used with Eleotin®, oral pharmaceutical drugs and insulin become safer, more efficacious, and less habit forming.

Please see Disclaimers on slides 3, 4, and 5.

## Advantage #2: Long Term Effects

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
None	None	Unknown	None	Semi-permanent efficacy

- With proven insulin resistance reduction, Eleotin® provides semi-permanent long term improvement while other treatments do not give such long term benefits.
- Most other treatments only have short term control benefits, and must be used permanently.
- But a person can stop Eleotin® with no harmful side effects after the body has attained structural change.

For more information, please contact [info@eastwoodcos.com](mailto:info@eastwoodcos.com)  
Please see Disclaimers on slides 3, 4, and 5.

## Advantage #3: Preventive Effects

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	<b>Eleotin®</b>
No	No	No	No	<b>Yes</b>

- A person who does not have diabetes can use Eleotin® for general health and preventive purposes. Other treatments do not offer such safe options.

# Conclusion

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
Short term and invasive treatment. Toxic and severe side effects. Resistance develops. Ever increasing dosages.	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.	<b>Long term and safe beneficial effects. General health improvements.</b>

- If you compare Eleotin® with other treatments from all perspectives, it's natural to conclude that Eleotin® is the only natural sourced option.

# As a Result,

Advertising Standards Canada (ASC) approved Eleotin® to be marketed as “**World’s #1** Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.

- World’s No.1 Doctor recommended: Over 3000+ doctors
- Over 2,500 Newspaper & Television Acclaims (including New York Times #1 Best Sellers)
- Researched/Clinically tested by Universities and Governments
- Strongly recommended by more than 4 Associations
- Licenses issued by 8 Government Authorities
- Best Diabetic & Hypertension Management Drug of the Year 2010\*
- As of 2018, more than 500,000 Users, and over 2,000 Youtube testimonials



# Recommendations of Medical Professionals



**Dr. Chu, Beijing China**  
“Because of Eleotin my husband doesn’t need any pharmaceutical drugs. He’s normal now.”



**Dr. L. Lipskaya, Bacteriologist**  
“After I started using Eleotin, I felt an improvement in my health conditions. Now I recommend Eleotin to every person who are suffering from Type II diabetes.”



**Dr. P. Singh**  
Ayurvedic Medicine  
“I want to recommend Eleotin especially to Type II diabetics. It will help them in controlling their blood glucose levels.”



**Dr. C. L. Broadhurst**  
“Eleotin is blend of many promising herbs that dramatically lower blood sugar.”



**Dr. D. Walker**  
“Eleotin is effective in regulating blood glucose levels. ”



**Dr. M. Sichel**  
“A pathfinding discovery in the reversal of diabetes.”



**Dr. E. Echano**  
“Everyone should know about this. I observed excellent clinical result. This unique herbal formulations long lasting effects are truly amazing.”

These are unsolicited third party opinions from unaffiliated individuals based on their own independent research. Except for claims referred to on slides 3, 4, and 5, EBM takes no responsibility for any claims.



# Clinical Studies, Publications, Approvals, and Licenses

## SUCCESS IS JUST THAT SIMPLE

The Analysis Results of 300 Diabetics Cases

ELEOTIN has been on the market in North America for 8 years, and hundreds of thousands diabetics are no longer suffering from diabetes because of it. In China, ELEOTIN has become well known, especially in neutralizing and adjusting/preventing complications from diabetes. ELEOTIN has shown great effectiveness.

To have a better understanding of ELEOTIN, we have done a detailed analysis by evaluating 300 diabetics. The 300 diabetics vary from ages 23 to 87. The period of time these patients took ELEOTIN varies from a short period of 1 month to a longer period of 8 months. Among these 300 cases, 256 were Type 2 diabetes (non-insulin dependent) and 44 were type 1 (insulin dependent).

Among the 256 patients with Type 2 diabetes, the blood glucose level (BGL) control and complications were different. Some of these patients had just recently been diagnosed, and others already had diabetes for decades. For these patients, some BGL were high during fasting, some were high 2 hours after meals, and some of them were high in both. Diabetics who were diagnosed for more than 5 years had one or more complications. In their clinical findings, symptoms of numbness and pain in the limbs and joints, fatigue, insomnia, skin itchiness, weak vision were present.

By taking ELEOTIN, 70% of these patients had stabilized their blood glucose level and 98% of their complications had improved. Some of them even had reduced dosage of pharmaceutical medications prescribed by physicians.

The following chart helps better explain the advantages of ELEOTIN:

1. This chart shows the percentage of people, Time taking ELEOTIN, and those with Reduced or Stopped Medication

Time on ELEOTIN	Number of Persons	People with Reduced/Stopped Medications	Percentage of People
Over 6 Months	96	62	64.6%
4 ~ 6 Months	142	59	41.5%
2 ~ 3 Months	40	5	12.5%
1 Months	22		

2. This chart shows the difference of symptoms and the BGL after taking ELEOTIN

BGL & Symptoms before taking ELEOTIN	Number of Persons	BGL & Symptoms improved after taking ELEOTIN	Better Transitions
High BGL	224	187	83.5%
BGL under control	32	32	100%
Insulin dependent	44	39	86.6%
Numbness on limb	56	47	83.9%
Fatigue	65	48	73.8%
Itchy skin	30	22	73%
Insomnia	34	25	73.5%
Weak vision	38	16	42.1%
Sweating	26	15	57.7%
Thirst	43	28	65.1%
Active urination at night	49	27	55.1%
Red swollen feet	3	2	66.7%
Impotence	7	6	85.7%

*The above statistics are from an extensive analysis of the 300 diabetes cases. We are grateful to see the dramatic effectiveness of ELEOTIN according to the numbers shown with those who gain from the benefits. ELEOTIN will show its unique and powerful results to nourish and repair if given the time and patience. By decreasing or stopping intake of ELEOTIN before fully investing the time and effort, more than 70% of diabetics will maintain their BGL in normal or close to normalcy without bouncing back.*

*Such powerful result is due in fact by its ability to alleviate insulin whose basic function is to control the amount of glucose in the blood. In doing so, ELEOTIN helps the establishment and repairing of B cells and increase in production of insulin. It can also balance the chemical reaction of insulin and beta cells and reduce the insulin resistance. By that the body will increase the metabolism of glucose.*

Please see Disclaimers on slides 3, 4, and 5.

# Clinical Studies, Publications, Approvals, and Licenses

약업신문

1998년 10월 8일 목요일

Executive

캐나다에 거주하는 교포의화자가 참여하고 교포가 운영하는 회사들이 공동으로 획기적인 당뇨병 치료제를 개발한 것으로 알려져 주목되고 있다.

최근 캐나다의 한 교포회사인 EBMR(Eastwood Bio-Medical Research Inc.)사가 발표한 바에 따르면 이번에 개발된 약물은 700여 차례의 임상실험을 실시한 결과 발병 6개월 이내의 성인형 당뇨병을 70% 이상 치료한 것으로 밝혀졌다.

P-700이라는 이 약물은 또 각종 천연약초에서 추출된 생약물질로 되어 있어 부작용과 내성이 전혀 없다고 EBMR 측은 발표했다.

EBMR은 이 약물이 혈당조절뿐 아니라 인슐린을 생산하는 췌장 베타세포의 기능을 감

화하고 근육조직에서 인슐린을 잡아주는 수용체를 다시 살아나게 해 당뇨병을 근본적으로 치료해 준다고 설명했다.

이번 당뇨병 치료제는 캐나다 캘거리대학교 당뇨연구센터가 기초연구 및 동물실험등을 실시했고 제출하는 EBMR측에서 추진하고 있는 것으로 전

ty Technologies International이라는 회사를 통해 EBMR과 상품개발 계약이 체결됐다.

이번 신약개발에 일조한 윤박사는 23년간 바이러스와 관련된 당뇨병의 원인과 예방에 대한 연구로 매우 높은 평가를 받고 있는 것으로 전해졌다.

EBMR측은 "윤박사가 노벨 의학상에 두 번이나 후보 수권된 권

위로 당뇨병 분야의 세계적 권위자"라고 소개했다.

한편 EBMR사는 호텔, 텔레커뮤니케이션 장비제조, 금융투자, 국제무역등의 관련업무를 하고 있는 이스트우드(Eastwood)의 계열사이며, 의학 관련 벤처기업으로 캐나다에 거주하는 한국인 교포 김영수(42)씨가 운영하는 회사이다.

(민경두기자)

**교포 획기적 당뇨병 치료제 개발**  
윤지원박사, 700여차례 임상 80% 완치

## Comments on Eleotin® by the Korean National Diabetes Association

Please see Disclaimers on slides 3, 4, and 5.

# Clinical Studies, Publications, Approvals, and Licenses



## 새 “당뇨병치료물질” 개발

“천연약초서 추출……부작용 전혀 없어”

EBMR한등 공동발표

캐나다 칼가리대 외대 당뇨연구센터와 개발 파트너인 EBMR사는 천연약초에서 새로운 당뇨병 치료물질을 개발하는 데 성공했다고 공동 발표했다.

이에 앞서 EBMR사는 이미 ‘P-700’을 이용한 건강차 ‘엘레오틴’을 지난 4월부터 북미지역에서 판매하기 시작했으며, 당뇨병치료 의약품 개발을 추진중이다.

공동개발자인 EBMR사는 캐나다 밴쿠버 소재의 표포기업인 이스트우드사(건영수 사장)의 제철사로 당뇨병과 암치료제를 전문적으로 개발중인 신약개발 전문회사다.

‘P-700’으로 명명된 이 당뇨병 치료물질은 천연약초에서 추출돼 기존 당뇨병 치료제에 비해 부작용이나 내성이 전혀 없는 것으로 나타났다고 칼가리대학과 EBMR사는 밝혔다.

EBMR사는 “임상실험 결과 ‘P-700’은 혈당을 조절하는 기존 당뇨병치료제 기능외에도 인슐린을 생산하는 췌장의 베타세포 기능을 강화하고, 근육 조직에서 인슐린을 잡아채는 수용체를 재생하는 효능까지 있다”고 밝혔다.

EBMR사는 “성인병의 대명사로 난치병으로 알려진 당뇨병을 치료할 수 있는 길을 보여준 셈”이라고 설명했다. 하지만 이런 신약이 개발돼 당뇨병자에게 보급되기까지 걸리는 기간은 대략 7~10년이 걸린다고 한다.

약사공론 1998. 10. 8. 제 3081 호

당뇨치료제 개발

캐나다 윤지원박사

캐나다에 거주하는 교포의학자에 의해 당뇨 치료에 획기적인 신약이 개발돼 화제가 되고 있다.

캐나다 캘거리 대학의 공식 발표에 따르면 캘거리대학교 당뇨연구센터 윤지원 박사가 발표한 ‘P-700’이라는 약은 이미 70여 차례의 임상실험을 통해 발병한 지 6개월 이내의 성인형 당뇨병에 대해서는 70% 이상을 정상으로 돌려놓을 수 있을 정도로 획기적인 효과를 보이고 있는 것으로 나타났다.

이런 당뇨병 관련 신약은 매우 비록 EBMR사와 캘거리대학 당뇨연구센터가 산학연계를 통한 공동연구를 추진한 성과로 신약의 상품화에 대한 권리는 EBMR사가 갖기로 계약했으며 이미 엘레오틴이라는 이름의 건강차로 응용되어 북미지역에

판매가 진행되고 있는 것으로 확인되었다. 윤지원박사(53)는 지난 22년간 바이러스와 관련된 당뇨병의 원인과 예방에 대한 연구로 이미 세계 일인자로 꼽히는 인물로 올년 KBS의 토크쇼인 박술퀴문상을 수상한 바 있다.

## Comments on Eleotin® by the Korean Pharmaceutical Manufacturers' Association

# Africa's Best Diabetic & Hypertension Management Drug in 2010\*



**INSTITUTE FOR GOVERNMENT RESEARCH & LEADERSHIP TECHNOLOGY**  
Office of the Country Director/CEO (Africa & Middle East)

The Managing Director/CEO  
Eleotin GP Ltd  
Goodnews Plaza, Suite A6  
4B, Agbaaku Street, Opebi, Ikeja  
Lagos State, South West Nigeria

Monday October 4 2010

Dear Sir,

## **BEST DIABETIC & HYPERTENSION MANAGEMENT DRUG OF THE YEAR 2010**

In the spirit of Nigeria's 50<sup>th</sup> Independence celebration, Institute for Government Research & Leadership Technology have the honour to make this award in favour of ELETOTIN GP LTD having out performed other companies in the production of fine Diabetic pharmaceuticals in Nigeria.

- 2) Some of the parameters and performance indices used are:
- Your compliance with Government regulatory laws and guidelines;
  - your prowess and contribution in the production of drugs;
  - product's high quality and value creation;
  - Corporate Marketing strategy;
  - Product's price and pricing strategy;
  - Product's acceptability, satisfaction and endorsement;
  - corporate general performance and track record;
  - product's unique selling points and competitive edge;
  - customer's continued patronage and or referrals;

2nd Floor, Oakland Centre, Australian Embassy Building, Plot 2940, Aguyi Ironsi Street  
Federal Capital Territory Maitama District, Abuja, Nigeria  
TEL: + 234 - 09 - 46029147,01 - 7306591, CEL: + 234 - 08031848907,08057507980 FAX: 09 - 4613217  
Web site: <http://www.instituteforgovernmentresearch.com>, e-mail: [instituteforgovernmentresearch@gmail.com](mailto:instituteforgovernmentresearch@gmail.com)

### **COUNCIL**

Prof. Kyari Tijani OFR Professor of Political Science/Public Administration, Chairman Prof. Ben Nwabueze CON, SAN Past Minister of Education  
Chief (Mrs) Priscilla Kuye FDM Past President Nigerian Bar Association Prof. Mahmood Mamdani Professor of Government  
Prof. Tony Travers Professor of Government Prof. David Gergen Professor of Public Leadership  
Dr. Blessings Chinsinga Associate Professor of Political Science & Administrative Studies  
Moses Essien Country Director/CEO (Africa & Middle East)



\*These are unsolicited third party opinions based on independent research. Except for claims referred to on slides 3, 4, and 5, EBM takes no responsibility for any claims. Please see Disclaimers on slides 3, 4, and 5.


## Growth Strategies & Current Research Projects: (1)

- 1. Having established a world leadership in the area of metabolic disorder treatments through the exclusive proprietary technology ~~700~~, claimed to be 'World #1 technology to lower insulin resistance by all natural means', Eastwood continues to develop products on the basis of ~~700~~ P technology. The redevelopments serve the more narrowly defined and specific needs of Alzheimer's disease, Parkinson's disease, Autism Spectrum, Cancer, kidney diseases, and transplant related issues,
- 2. Having already accumulated promising initial clinical results in the areas of autoimmune diseases and addiction treatments, we will continue to further our efforts to develop products. Joint research projects are under way in cooperation with a few international research institutions and a few perennial Nobel Prize nominees.

## Growth Strategies & Current Research Projects: (2)

- 3. Having 'all natural' products that can replace or substitute synthetic prescription drugs such as statins, ibuprofen, estrogen with little or no side effects, we will continue to expand the list of synthetic prescription drugs which we can
- 4. Having the need for high quality organic plant sources for our herbal products, we embarked on an advanced agricultural project on a property 50km east of Seoul Korea. The property is known to be the single largest privately owned property in Greater Metropolitan Seoul area. Dr. Youngsoo Kim, CEO, owns this property.

# Testimonials



**We have over 5,000 video testimonials on Youtube by users and doctors with all real names and many contact information to verify.**

Please see Disclaimers on slides 3, 4, and 5.

# Established Retail Lines



## Eleotin® Bentley

- Helps promote healthy glucose levels.
- Long-term blood glucose normalization effects.
- General health improvement.



## Eleotin® Ma5

- Powerful anti-oxidation powers that are preserved superbly.
- High quality Vitamin C group ingredients.

# Established Retail Lines



## Eleotin® LBM

- For hyperactivity of the liver (high blood pressure).
- To cut the vicious cycle between high blood sugar and high blood pressure caused by prescription drugs.



## Eleotin® Podo-Protection Socks

- Anti-Fungal & Anti-Bacterial.
- Auto Regulating Mesh Top.
- Treated Inner Toe Seam.
- Holistic & Gentle Neck Pressure.

# Founder - Dr. Youngsoo Kim



- Advises Various Governments and senior management of numerous Korean firms including Hyundai, Gold Star, and Samsung
- CEO of Mutsumi Enterprises Canada Corp. 1991-1995
- Vice President of Toshin Butsuryu (Toyota Automobile Group Japan) 1991-1995
- Assistant Professor of Finance at the University of Alberta in Edmonton 1987
- Massachusetts Institute of Technology (Ph.D. in Economics) 1987
- Section director at Ministry of Industry and Commerce in 1979
- Protocol secretary in the Korean Presidential Palace 1978
- Section Director in Ministry of Foreign Affairs in 1977

# Board of Directors

## **Yunji Kim**

*President, CEO and Director*

- President since April 2013, Director since October 2012
- New York State Bar admission 2012
- LL.M. in Taxation, Georgetown University Law Center, 2011

## **Peter Chen**

*CFO and Director*

- Executive Director of Proterra Management Group Inc.

## **Dr. Terrance Owen**

*Director*

- Director of Pacific Paredyme Energy Inc.
- CEO of CellMedX Corp.
- President and CEO of Nuva Pharmaceuticals Inc. until June 2013

## **Dr. Marcus Kuypers**

*Director*

- Medical Doctor
- Physician at AB Staffing since November 2011
- Accretive Health from October 2011 to February 2013
- Doctors Home Visits from September 2001 to August 2011
- Emergency Medicine physician since November 2011

# Appendix - Financial Information

**Most updated information available upon request**

**[www.eleotin.ca](http://www.eleotin.ca)**



**TSX-V: EBM**

**Yunji Kim**

**Unit 1130-4871 Shell Road Richmond, B.C. Canada,  
V6X 3Z6**

**604.247.2100 or 1.888.669.4372**

**[yunjikim@eastwoodcos.com](mailto:yunjikim@eastwoodcos.com)**

**[www.eleotin.ca](http://www.eleotin.ca)**